Rivastigmine: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<applet load="" size="480" color="" frame="true" spin="on" Scene ="Rivastigmine/Riv/1" align="right" caption="Rivastigmine, also known as Exelon"/> | <applet load="" size="480" color="" frame="true" spin="on" Scene ="Rivastigmine/Riv/1" align="right" caption="Rivastigmine, also known as Exelon"/> | ||
===Better Known as: Exelon=== | ===Better Known as: Exelon=== | ||
* Marketed By: <br /> | * Marketed By: Novartis<br /> | ||
* Major Indication: [[Alzheimer's Disease]]<br /> | * Major Indication: [[Alzheimer's Disease]]<br /> | ||
* Drug Class: [[Acetylcholinesterase]] Inhibitor | * Drug Class: [[Acetylcholinesterase]] Inhibitor | ||
* Date of FDA Approval (Patent Expiration): <br /> | * Date of FDA Approval (Patent Expiration): 2007 (<br /> | ||
* 2006 Sales: $220 Million<ref>Irena Melnikova, Therapies for Alzheimer's disease, Nature Reviews Drug Discovery 6, 341-342 (May 2007)</ref> | * 2006 Sales: $220 Million<ref>Irena Melnikova, Therapies for Alzheimer's disease, Nature Reviews Drug Discovery 6, 341-342 (May 2007)</ref> | ||
* Importance: One of the the first treatments for the symptoms of [[Alzheimer's Disease]], although no definitive proof exists as to whether it alters the progression of the disease. | * Importance: One of the the first treatments for the symptoms of [[Alzheimer's Disease]], although no definitive proof exists as to whether it alters the progression of the disease. | ||